---
title: Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins
nct_id: NCT02237781
overall_status: UNKNOWN
phase: PHASE2, PHASE3
sponsor: University of Athens
study_type: INTERVENTIONAL
primary_condition: Female Infertility
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02237781.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02237781"
ct_last_update_post_date: 2014-09-11
last_seen_at: "2026-05-12T06:30:06.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins

**Official Title:** Prospective Randomized Trial on the Level of Anti-Mullerian Hormone (AMH) in Women Undergoing Controlled Ovarian Stimulation for IVFwith Gonadotropins.

**NCT ID:** [NCT02237781](https://clinicaltrials.gov/study/NCT02237781)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** University of Athens
- **Collaborators:** Lito Maternity Hospital
- **Conditions:** Female Infertility
- **Start Date:** 2014-10
- **Completion Date:** 2015-12
- **CT.gov Last Update:** 2014-09-11

## Brief Summary

Anti-Mullerian Hormone (AMH) is produced only in small ovarian follicles with quite stable levels during the cycle. There is not yet sufficient data to inform couples undergoing IVF about the effect of ovarian stimulation on the levels of AMH due to the increasing size of follicles and chances of success of the method.

## Detailed Description

Patients undergoing IVF will be included in the study. All patients will be counseled regarding their prognosis. Anti-Mullerian Hormone (AMH) will be measured prior to the initiation of IVF and during ovarian stimulation. Patients will be stimulated with a short GnRH-antagonist protocol. All women will have measurements of serum FSH and estradiol (E2) and a pelvic sonogram on the second day of their cycle. Ovarian stimulation will be initiated with of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH. The dose of gonadotropins will depend on the levels of estradiol and FSH prior stimulation. All patients will be re-evaluated on day 3 and 5 of the stimulation (measurment of AMH, E2 and pelvic sonogram), and dosage adjustments will be made and the antagonists (Cetrorelix or ganirelix 0.25 mg/day) will be initiated on day 5. Measurment of AMH, E2 and pelvic sonogram to conferm the size of follicles will be continue every second day untill the oocyte retrieval. When at least 2 follicles reach an average diameter of 17 mm, final oocyte maturation will be triggered with 10,000IU of hCG ( Pregnyl, Organon, Greece Inc.). Oocyte retrieval will be performed 34 to 36 hours later. Patients with successful fertilization will have embryo transfer under sonographic guidance on day 3 after retrieval.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 50 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* All infertile women undergoing ovarian stimulation for IVF.

Exclusion Criteria:

* Women who can not undergo IVF
```

## Arms

- **AMH levels** (EXPERIMENTAL) — Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.

## Interventions

- **Gonadotropins** (DRUG) — The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .

## Primary Outcomes

- **Level of AMH** _(time frame: 6 months)_ — Anti-Mullerian Hormone (AMH) will be measured prior to the initiation of treatment and during ovarian stimulation.

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02237781.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02237781*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*